Size: px
Start display at page:

Download ""

Transcription

1

2

3

4

5

6

7

8

9

10 wtlf',o)a> 7+l+rv tlljeir>

11

12

13

14 ar"4-r.ha>&fr,

15

16

17

18 v l:s r ev77, l: h >i-rl /v, >, v +t v tv. c r: BrvvTTVF 7)vlrltvr2. U Fe? ep77 '/l lx/vtjvrr. Y FdtevTTt f." E],y')vt>h\, t^' v Fu2 us

19

20

21

22

23

24

25 Press

26 26mg 26ng 25roe

27 =tv'sy l.$e25mg

28

29

30

31 I Am J Obstet Cynecol. 2002; 186(2):

32 2 J Perinat Med- 20ll Jan;39(l):23{.

33

34

35 ro s Af Med J May 7 :5 1(t9):660-3.

36

37

38

39 )(nsrn

40 OXYTOCIN iniection

41

42 2ffopg

43

44 /Ei(rrii000l fia+>i},,cf0ti ffil *w+rrr^',r'frivj 2.gmc

45

46

47 FfrSS.Eil,$ *+'/\->> t)rezl. \:./^\,,^cooh

48

49

50 25mg 25me 25mg 25mc 1.4% {Jm) o.o% (obl, 2.4y" (36J) s.2ol" (ll EJ) o.o% (of) o.s% (t FJ) o.o% (o9j) 4.8% (lofrl) 0.5% (r Fl) t.e% GEI) o.o% (06l) o.o% $% on) r.r% (6&) r.8% (8n) o.o% (of))

51 7.8% (s&j) o.o% (ofd o.o% (o 6J) 7.8"/" (s'tr) e.2"/" (6'/) 7.8./" (6n, 4.7"/" Q n) o.o% (o fij) o.o% (ofd o.o% (odj) 4.7% Gn) 7.7% 6n) 3.r% Qfi,) o.o% (ofl) o.o% (ofrd 1.6% (t El)

52

53 AUC*-. C.".. Cxh 't- 4.22'l p<0.00 p< [-o 30 -o r?l ote

54

55 uunau[j ANl' AlrytrNrs-l RA f tun Posology ahd metbod of administration Recommended Dosing The dose ofjanuvia is 100 mg once daily. The recommendedose ofjanuvta is 100 mg once daily. Special ponulations Pqtients with Renal Insufficiencv Renal impaiment For patients with mild renal insrifficiency (creatinine cleamnce For patients with mild renal impairment (creatinine clearance [CrCl] [CrCl] greater than or equal to 50 ml/miq approximately ) 50 mvmin), no dose adjustment for Januvia is required. coresponding to serum creatinine levels of less than or equal to 1.7 mgldl n.men and less than or equal to 1.5 mgldl in wdmen} no dosage adjustment for JANUVIA is required. - For patients with moderate renal impabment (CrCl )30 to <50 mumin), the dose of Januvia is 50 mg once daily. For patienls with moderate renal insufticiency (CrCl greater than For patients with severe renal impairment (Crcl <0 mumin) or or equal to 30 to less than 50 ml/min, approximatelywith end-stage renal disease (ESRD) r quiring haemodialysis or corresponding to serum crcatinine levels of greater than t,7 to peritoneal dialysis, tle dose ofjanuvia is 25 mg once daily, Januvia less than or equal to 3.0 mg/dl in men md greater than 1.5 to less may be administered wilhout regard to the timing ofdialysis. than or equal to 2.5 mgdl in women), rhe dose of JANLIVIA is 50 mg once daily. For patients with severe renal insuf'ficiency (CrCl less than 30 nrl/min, approximately conesponding to serum creatinine levels ot greater than 3.0 mg/dl in men and greater than 2.5 ng/dl n women) or with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis, the dose oi.i,,nuvl{ is Z5 mg once daily. JANUVIA may be administered without regard to the timine of dialvsis. 50mg 25mg 5omg

56

57

58

59 ?'Hi;: HiEfr -ftee'f, -.. I'6'fiit ' " 'trie+e*di*ia3 t!6a?. $![a*len*o.b l*ah, tl*:1.5<cr<zj ' tlfr 1.3 < G<21 W&1.Mt :EX W. fi M. tt! ro. I

60 $ mso

61 (n=6),fr l'd-^ O.2mc

62

63 FFv-/>

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78 tetuae?i>6'w}e EiE

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

/i 1,,._ /\YF*r$-/t, /.:/ lrfi-/l ty)t- /:V-fi-)v '+l'y)t * /;v--t:--l.'>l la- ' i>rtv /iv-i.-,v /r/tv /, / 'v1 -;l- /v F;:*#(2) A^*f *#(3) t45.5i *7v>/tvz

More information

Table 1 Patients with various renal function * Ccr, Creatinine clearance ml/min per 1. 48 m2 ** C.V.D., Cerebral vascular disease ; C.R F., Chronic renal failure ; H.D., Hemoclialysis ; D., Dialyzer ;

More information

2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1

2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1 Mg-LPSO 2566 2016 3 2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1 1,.,,., 1 C 8, 2 A 9.., Zn,Y,.

More information

Nobelman 絵文字一覧

Nobelman 絵文字一覧 Nobelman i-mode EZweb J-SKY 1 88 2 89 3 33 4 32 5 5 F[ 6 6 FZ 7 35 W 8 34 W 9 7 F] W 10 8 F\ W 11 29 FR 12 30 FS 13 64 FU 14 63 FT 15 E697 42 FW 16 E678 70 FV 17 E696 43 FX 18 E6A5 71 FY 19 117 20 E6DA

More information

Q E Q T a k Q Q Q T Q =

Q E Q T a k Q Q Q T Q = i 415 q q q q Q E Q T a k Q Q Q T Q = 10 30 j 19 25 22 E 23 R 9 i i V 25 60 1 20 1 18 59R1416R30 3018 1211931 30025R 10T1T 425R 11 50 101233 162 633315 22E1011 10T q 26T10T 12 3030 12 12 24 100 1E20 62

More information

CRA3689A

CRA3689A AVIC-DRZ90 AVIC-DRZ80 2 3 4 5 66 7 88 9 10 10 10 11 12 13 14 15 1 1 0 OPEN ANGLE REMOTE WIDE SET UP AVIC-DRZ90 SOURCE OFF AV CONTROL MIC 2 16 17 1 2 0 0 1 AVIC-DRZ90 2 3 4 OPEN ANGLE REMOTE SOURCE OFF

More information

fff,smg l?t)- fle5mg ---o--. 5 mg ----c- l0 mg +20 mg Cmu 6c/mL) 10mg 20mg (mean t SD) (nglml) ft! omm fij /mm lfi o.tg e triz [h] N-12 (23.0) (27.e) (2.00-6.00) I E 2 El AUC",""") C**,,, t*,,,0) trn,""

More information

0

0 G 1 G 2 3 2 3 4 14 f f 0 G G G G a1 GF f 1 1 1 L I H M K J f 1 5 G G G G GG Aa G f 6 G G G Aa G f 1 2 1 2 3 45 C 123 3 4 1234 5 6 7 123 e 8 9 0 1 2 3 4 1 2 3 4 14 f N f f f 1 1 2 12 3 4 5 6 f 3 G G 1 12

More information

橡ボーダーライン.PDF

橡ボーダーライン.PDF 1 ( ) ( ) 2 3 4 ( ) 5 6 7 8 9 10 11 12 13 14 ( ) 15 16 17 18 19 20 ( ) 21 22 23 24 ( ) 25 26 27 28 29 30 ( ) 31 To be or not to be 32 33 34 35 36 37 38 ( ) 39 40 41 42 43 44 45 46 47 48 ( ) 49 50 51 52

More information

DFC Dialysis Facility Compare g/dl UPR65% UPR BUN BUN/ BUN NEJM, March10,2005 Anemia of C

DFC  Dialysis Facility Compare g/dl UPR65% UPR BUN BUN/ BUN NEJM, March10,2005 Anemia of C HemodialysisReview Article: Medical ProgressNEJM, Nov.4, 2010 H23.1 80 20 1 Dialyser NEJM 1 6.6 15.6 21.7 1 21.7 AV fistula 3 1 4 1 1980 Kt/V urea Vml t 1.4 8 12 DFC: Dialysis Facility Compare DFC http://www.cms.gov/dialysisfacilitycompare/

More information

CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover

CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover VOL.26 S-2 CHEMOTHERAPY Gentamicin (GM), Dibekacin (DKB), Tobramycin Fig. 1 Protein concentration and protein binding rate Table 2 Protein binding rate of PC-904 in serum of healthy adults, and patients

More information

日本化学療法学会雑誌第51巻第2号

日本化学療法学会雑誌第51巻第2号 piperacillin piperacillin PIPC. g Cmax CL PIPC CL CLR CLNR CL PIPC g g Cmax PIPC Key words: piperacillin Piperacillin PIPC PIPC g g PIPC Cmax g g ml g g ml g g ml T T T PIPC g g T Ccr ml min AUCCmax PIPC

More information

 

  21 2418:00 19:30 19 1 18 20 2 3 4 15 5 21 6 35 2006 2007 25 2008 110 1,000 30 40 19 75 100 600 7 10 37 12 55 17 55 20 70 13 1.5 9 10 14 FJ 15 18 19 20 8 24 29 9 12 23 22 23 10 24 25 14 26 2055 1.32 11

More information

CHEMOTHERAPY MAY 1988

CHEMOTHERAPY MAY 1988 VOL. 36 NO. 5 Table 1. Subjects studied B. W. Body weight B. H. Body height Abbreviations Ccr Endogenous creatinine clearance PSP Phenolsulfonphthalein test for 15 min BUN Blood urea nitrogen Scr Serum

More information

Microsoft Word - 表紙資料2-4

Microsoft Word - 表紙資料2-4 (1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)

More information

調査報告書

調査報告書 8 15 1 2 3 4 1 2 VTR 3 4 19 19 19 1 2 3 4 5 6-1 - 23 1 2 VTR VTR MA MA 3 2 34 1 BPO - 2 - 2 3 4 5TBS 6 41 1 2 3 4 5 63 1 520 2 3 53 17 4 17 61 17 6 12 69 17 8 7 78 17 10 16 2005 SP 86 17 12 11-3 - 95 18

More information

2.

2. 2. 10 2. 2. 1995/12006/111995/42006/12 2. 10 1995120061119954200612 02505 025 05 025 02505 0303 02505 250100 250 200 100200 5010050 100200 100 100 50100 100200 50100 10 75100100 0250512 02505 1 025051205

More information

EP7000取扱説明書

EP7000取扱説明書 EP7000 S0109-3012 3 47 811 1213 1419 2021 53 54 5560 61 6263 66 2223 2427 2830 3133 3436 3740 4142 4344 45 46 4750 5152 2 4 5 6 7 1 3 4 5 6 7 8 9 15 16 17 18 13 EP7000 2 10 11 12 13 14 19 20 21 22 23 24

More information

1 2

1 2 1 2 4 3 5 6 8 7 9 10 12 11 0120-889-376 r 14 13 16 15 0120-0889-24 17 18 19 0120-8740-16 20 22 21 24 23 26 25 28 27 30 29 32 31 34 33 36 35 38 37 40 39 42 41 44 43 46 45 48 47 50 49 52 51 54 53 56 55 58

More information

3 5 6 7 7 8 9 5 7 9 4 5 6 6 7 8 8 8 9 9 3 3 3 3 8 46 4 49 57 43 65 6 7 7 948 97 974 98 99 993 996 998 999 999 4 749 7 77 44 77 55 3 36 5 5 4 48 7 a s d f g h a s d f g h a s d f g h a s d f g h j 83 83

More information

K 1 mk(

K 1 mk( R&D ATN K 1 mk(0.01 0.05 = ( ) (ITS-90)-59.3467 961.78 (T.J.Seebeck) A(+ T 1 I T 0 B - T 1 T 0 E (Thermoelectromotive force) AB =d E(AB) /dt=a+bt----------------- E(AB) T1 = = + + E( AB) α AB a b ( T0

More information

il E ------------= 5E 1B H 171819 l /\yl-.';t'.-/t rl -,1i* [ F,li*/L .7 F rli- r" )'> F,f.*)v 'u,, tv ,/tvz '/u, )v 7./:/, )v7 /7tvz t'//lv7 oebrft tt ''No,2R.4

More information

,717=Z 8,04r,s00 I 191,500 3,634,5101 slo 3oo Fl x (+E s954,\+ ElEr2s,, \) *+Errslfir+Errfrl Ir* , \v -il- )v )\2Fif- lv ./l: tt/tv^ Y7 /v7 ,7,v^,/tv YT tv^ 4a tv7 >rtv7 1D s3.so] * E r-il-2f..--_

More information

M1 TSH T 3 T 4 2 T 1 2 Plummer 3 TSH TSH K 5 7 TSH TSH Plummer TSH TSH TSH TSH T 4 T 3 TSH T 4 T 3 TSH TSH or Plummer Plummer or a) 1. 2. 3. b) 1. T 4 T 3 2. TSH 0.1 U/ml 3. TSH TRAb TSAb 4. 1) a) 1

More information

mr0805.indd

mr0805.indd 62 MAY 2008 MAY 2008 63 64 MAY 2008 MAY 2008 65 66 MAY 2008 MAY 2008 67 68 MAY 2008 MAY 2008 69 70 MAY 2008 MAY 2008 71 72 MAY 2008 MAY 2008 73 74 MAY 2008 MAY 2008 75 76 MAY 2008 MAY 2008 77 78 MAY 2008

More information

L LM L B 12 c c L G L G L G L G L G L G bcb c L K J a B C 19 0de G c A f b b 123 G G 1 f 5 G G G G Gf d 09 d B 3 G f 3 G G G 1 2 1 2 G G G 1 G 1 G 2 3 1 2 G G G 1 G B B 1 2 3 4 5 6 7 8 9 G 2 2 B 12 f 4

More information

「  (会の名称)     」のご案内

「  (会の名称)     」のご案内 千葉県病院薬剤師会北部支部会員各位 16 年 2 月吉日 千葉県病院薬剤師会北部支部 学術講演会 北部支部長土谷隆紀謹啓時下ますますご清祥の段 お慶び申し上げます さてこの度 千葉県病院薬剤師会北部支部 学術講演会を下記の通り 開催させて頂く事となりました つきましてはご多忙中のこととは存じますが万障繰り合わせの上 ご出席賜りますようにお願い申し上げます 謹白記 日時 : 平成 28 年 4 月 15

More information

社葬事前手続き

社葬事前手続き 2 ... 4... 4... 5 1... 5 2... 5 3... 5 4... 5 5... 5 6... 5 7... 5 8... 6 9... 6 10... 6... 6 1... 6 2... 6 3... 7 4... 7... 8 1 2.... 8 2 2.... 9 3 4.. 3 4. 1 2 3 4 5 6 7 5 8 9 10 I 1 6 2 EL 3 4 24 7

More information

2011 2012 4 8 C D! A B

2011 2012 4 8 C D! A B 2011 2012 4 8 C D! A B C D 2013 2014 5/ 6 7 9 11/ 12 1 3 5/6 7 9 11/12 1 3 5 6 7 1971 2003118 9 196338) 7651) 2006 1 3 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 The Women of Lockerbie 19881221 16243

More information

2 1 2 3 27 2 6 2 5 19 50 1 2

2 1 2 3 27 2 6 2 5 19 50 1 2 1 2 1 2 3 27 2 6 2 5 19 50 1 2 2 17 1 5 6 5 6 3 5 5 20 5 5 5 4 1 5 18 18 6 6 7 8 TA 1 2 9 36 36 19 36 1 2 3 4 9 5 10 10 11 2 27 12 17 13 6 30 16 15 14 15 16 17 18 19 28 34 20 50 50 5 6 3 21 40 1 22 23

More information

syuryoku

syuryoku 248 24622 24 P.5 EX P.212 2 P271 5. P.534 P.690 P.690 P.690 P.690 P.691 P.691 P.691 P.702 P.702 P.702 P.702 1S 30% 3 1S 3% 1S 30% 3 1S 3% P.702 P.702 P.702 P.702 45 60 P.702 P.702 P.704 H17.12.22 H22.4.1

More information

土壌環境行政の最新動向(環境省 水・大気環境局土壌環境課)

土壌環境行政の最新動向(環境省 水・大気環境局土壌環境課) 201022 1 18801970 19101970 19201960 1970-2 1975 1980 1986 1991 1994 3 1999 20022009 4 5 () () () () ( ( ) () 6 7 Ex Ex Ex 8 25 9 10 11 16619 123 12 13 14 5 18() 15 187 1811 16 17 3,000 2241 18 19 ( 50

More information

381

381 P381 P386 P396 P397 P401 P423 P430 P433 P435 P437 P448 P451 P452 381 382 383 384 385 3.0mm 5.0mm 3.0mm 5.0mm SK SK3.0mm SK5.0mm 3.0mm PUR PUR3.0mm 2.0mm 2.0mm3.0mm 2.5mm 2.5mm3.0mm 3.0mm 5.0mm 3.0mm 1.8mm

More information

, ,

, , 41 42 73 121 121 10 122 11 122 12 131 13 131 15 10 133 16 11 133 17 12 136 18 13 141 19 14 141 20 15 146 21 16 149 22 17 149 23 174 18 24 73 19 241,301 25 20 242,301 (1) 26 21 331 27 22 241,341 28 23 242,341

More information

03J_sources.key

03J_sources.key Radiation Detection & Measurement (1) (2) (3) (4)1 MeV ( ) 10 9 m 10 7 m 10 10 m < 10 18 m X 10 15 m 10 15 m ......... (isotope)...... (isotone)......... (isobar) 1 1 1 0 1 2 1 2 3 99.985% 0.015% ~0% E

More information

untitled

untitled 186 17 100160250 1 10.1 55 2 18.5 6.9 100 38 17 3.2 17 8.4 45 3.9 53 1.6 22 7.3 100 2.3 31 3.4 47 OR OR 3 1.20.76 63.4 2.16 4 38,937101,118 17 17 17 5 1,765 1,424 854 794 108 839 628 173 389 339 57 6 18613

More information

untitled

untitled 1. 3 14 2. 1 12 9 7.1 3. 5 10 17 8 5500 4. 6 11 5. 1 12 101977 1 21 45.31982.9.4 79.71996 / 1997 89.21983 41.01902 6. 7 5 10 2004 30 16.8 37.5 3.3 2004 10.0 7.5 37.0 2004 8. 2 7 9. 6 11 46 37 25 55 10.

More information

1.. 1 ll a ii. 1i. i f 1 1 a. a. i. t. 1 fi fi. t i j fj i. j ;i 1. i. aa a

1.. 1 ll a ii. 1i. i f 1 1 a. a. i. t. 1 fi fi. t i j fj i. j ;i 1. i. aa a 1.. 1 ll a ii. 1i. i f 1 1 a. a. i. t. 1 fi fi. t i j fj i. j ;i 1. i. aa 1 111 0 0 0 0 a I E l21 1fi i L < i i;i1=t ii 111 1; ai i ti a t T ;,, l 1i.... E 11fi i 1t l l t2 1i i1 t Ea li )2 0 u 0 1f )2

More information

18 (1) US (2) US US US 90 (3) 2 8 1 18 108 2 2,000 3 6,000 4 33 2 17 5 2 3 1 2 8 6 7 7 2 2,000 8 1 8 19 9 10 2 2 7 11 2 12 28 1 2 11 7 1 1 1 1 1 1 3 2 3 33 2 1 3 2 3 2 16 2 8 3 28 8 3 5 13 1 14 15 1 2

More information

日本化学療法学会雑誌第61巻第4号

日本化学療法学会雑誌第61巻第4号 μ μ μ μ μ μ Key words I β μ Sex Age (years) Height (cm) Evaluation items Table1.Characteristics of patients 1. mg/kg/day (n14) 2.5 mg/kg/day (n9) 5. mg/kg/day (n9) Total (n32) male 12 8 7 27 female 2 1

More information

untitled

untitled 20 2 14 18 10 16 1 1.0mg 0.035mg 2 1 20 2 14 18 10 16 1 1 1 52 1 1 21 7 28 1 29 2 1 20 1 24 18 10 16 1 1 21 7 28 1 29 1 NET 1.0mg EE 0.035mg *NET *NET 1999 2007 *NET *NET 88 NSAIDs GnRH GnRH NSAIDs 20

More information

000 001

000 001 all-round catalogue vol.2 000 001 002 003 AA0102 AA0201 AA0701 AA0801 artistic brushes AA0602 AB2701 AB2702 AB2703 AB2704 AA0301 AH3001 AH3011 AH3101 AH3201 AH3111 AB3201 AB3202 AB2601 AB2602 AB0701 artistic

More information

Title 歯性病巣の関連する皮膚疾患におけるビオチンの効用 Author(s) 高橋, 愼一 ; 川島, 淳子 ; 森本, 光明 ; 山根, 源之 Journal, (): - URL Right Posted at the Inst

Title 歯性病巣の関連する皮膚疾患におけるビオチンの効用 Author(s) 高橋, 愼一 ; 川島, 淳子 ; 森本, 光明 ; 山根, 源之 Journal, (): - URL   Right Posted at the Inst Title 歯性病巣の関連する皮膚疾患におけるビオチンの効用 Author(s) 高橋, 愼一 ; 川島, 淳子 ; 森本, 光明 ; 山根, 源之 Journal, (): - URL http://hdl.handle.net/10130/526 Right Posted at the Institutional Resources for Unique Colle Available from

More information

A A OT 2 A OT A OT A A OT 4 OT A A OT A OT A OT A 3 OT 1 2 OT 2 2 1 2014105 26.5.12 26.5.27 26.6.4 26.9/116 OTPT 10/101 26.9.292 26.6/26 26.5/2727.5/31 2/ 2/ H26.10.177 26.10.21 22 27.2 27.3 27.4.1 27.4.21

More information

FM改正規格原案 目次.PDF

FM改正規格原案 目次.PDF i ii iii 535 4585 5 0.1 10 10 15 1 0 1 0 1 3 2 1 2 3 50 1.2 600 5 600 600 5 1 2 3 1 1 2 1 4 R Ra R R'?? 2 1 1 2 R' R Ra R??? 4 2 70 1000 8 1 1 8 10 2 5 510203045607590105 120 10 2 23 3 10 30 1 10 30 55

More information

1 Ricci V, V i, W f : V W f f(v ) = Imf W ( ) f : V 1 V k W 1

1 Ricci V, V i, W f : V W f f(v ) = Imf W ( ) f : V 1 V k W 1 1 Ricci V, V i, W f : V W f f(v = Imf W ( f : V 1 V k W 1 {f(v 1,, v k v i V i } W < Imf > < > f W V, V i, W f : U V L(U; V f : V 1 V r W L(V 1,, V r ; W L(V 1,, V r ; W (f + g(v 1,, v r = f(v 1,, v r

More information

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii

More information

13Ad m in is t r a t ie e n h u lp v e r le n in g Ad m in is t r a t ie v e p r o b le m e n,p r o b le m e n in d e h u lp v e r le n in g I n d ic

13Ad m in is t r a t ie e n h u lp v e r le n in g Ad m in is t r a t ie v e p r o b le m e n,p r o b le m e n in d e h u lp v e r le n in g I n d ic 13D a t a b a n k m r in g R a p p o r t M ィC Aa n g e m a a k t o p 19 /09 /2007 o m 09 :3 1 u u r I d e n t if ic a t ie v a n d e m S e c t o r BJB V o lg n r. 06 013-00185 V o o r z ie n in g N ie

More information

★ソフィアンズガイド2016_A5.indd

★ソフィアンズガイド2016_A5.indd SOPHIANS GUIDE 2016 CONTENTS Sophians' Guide 2016 2 Sophia University 3 4 Sophians' Guide 2016 Sophia University 5 Sophians' Guide 2016 6 Sophia University 7 8 Sophians' Guide 2016 Sophia University 9

More information

zrtt-^fi.-.zl, . i f.,t, -zl, +lv)t* v-,f,.- L,)l;f- L ,)ll'- L,a,v^ i>/,va 4/ tvz /'/ tvz t\/ 1-n Ef, (3) 4 551drtl }E--EE(2] 4-JZG. o luanrr i *0.5i 2oomi I T/iE] l 9/ t4 9/15 :r-r'87>

More information

プリント

プリント 130 100 70 100 127% ECO.R IS 300 200 100 100 280% 0 ECO.R IS 120% 120 100 100 80 new ECO.R LS 121% 120 127% 100 100 80 new ECO.R LS ECO.R LS 130% 130 100 100 70 ECO.R LS 120 100 80 100 116% 122% new ECO.R

More information

109

109 108 1 2 3 109 110 111 112 1 c c < c c< B N a d 1 2 3 5 8 9 0 ; 2c< rc a h 3c 113 1p 2c< 3c< a r 4cc 1p 2 c 3c< c p a c 4p 5 c rr c c Cr m e 114 1 c c < c< B N d a 1 3 5 9 0 ; 2c< B ; p c< BN50; ar h 3c

More information

1.... 1 1.1.... 1 1.2.... 2 1.3.... 3 2.... 5 2.1.... 6 2.1.1.... 6 2.1.2....11 2.2.... 12 2.2.1.... 12 2.2.2.... 17 2.3.... 19 2.3.1.... 19 2.3.2.... 32 2.3.3.... 38 2.4.... 39 2.4.1.... 39 2.4.2....

More information

1/68 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 平成 31 年 3 月 6 日現在 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載

1/68 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 平成 31 年 3 月 6 日現在 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載 1/68 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 平成 31 年 3 月 6 日現在 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載のない限り 熱容量を考慮した空き容量を記載しております その他の要因 ( 電圧や系統安定度など ) で連系制約が発生する場合があります

More information

2009年133巻3号3月号.indb

2009年133巻3号3月号.indb Folia Pharmacol. Jpn.133 1 2 Chiroscience UCB S RR-..% AA C IC C/A A/ A R- II/ III II/III Chiroscience UCB S 1 - E-mail: koji_taya@maruishi-pharm.co.jp Author: Koji Taya, Satoshi Shimizu Title: Levobupivacaine

More information

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.

More information

™…{,

™…{, 16:30-17:40 1-36 1-37 1-38 1-39 1-40 1-41 1-42 33 10:00-11:10 1-43 1-44 1-45 1-46 1-47 1-48 1-49 12:00-12:50 LS4 34 16:30-17:40 1-50 1-51 1-52 1-53 1-54 1-55 1-56 35 16:30-17:40 1-57 1-58 1-59 1-60 1-61

More information